Koleen Eisele

Ef fi cacy of SERD / SERM Hybrid-CDK 4 / 6 Inhibitor Combinations in Models of Endocrine Therapy – Resistant Breast Cancer

M. Ellis, Shunqiang Li, R. Crowder, 2015 .

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.

X. Mu, J. Bienkowska, Zhou Zhu, 2021, Cancer cell.

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

J. Christensen, G. Han, T. Affolter, 2014, BMC Cancer.

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer

M. Ellis, Shunqiang Li, R. Crowder, 2015, Clinical Cancer Research.

60PMECHANISM OF ACTION FOR COMBINED CDK4/6 AND ER INHIBITION IN ER POSITIVE BREAST CANCER

M. Koehler, T. Vanarsdale, K. Arndt, 2014 .